Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025 -13254.5% Operating margin3 -48.2% Revenue growth, 20253 Where the money goes Where each dollar of revenue went, fiscal 2025 Research and development Interest
Research and development 83¢ $3.9M Interest 17¢ $812.0K Out of $88.0K in revenue.3
Financial statements
Income statement Balance sheet Cash flow
Annual Quarterly
Revenue4 5 6 7 8 3 $88.0K in 2025−37% since 2019 0 $100.0K $200.0K $300.0K 2019: $140.0K $140.0K 2019 2020: $163.0K $163.0K 2020 +16% 2021: $135.0K $135.0K 2021 −17% 2022: $141.0K $141.0K 2022 +4% 2023: $202.0K $202.0K 2023 +43% 2024: $170.0K $170.0K 2024 −16% 2025: $88.0K $88.0K 2025 −48% Operating income4 5 6 7 8 3 -$11.7M in 2025−6% since 2019 -$40.0M -$30.0M -$20.0M -$10.0M 0 2019: -$12.4M -$12.4M 2019 2020: -$15.2M -$15.2M 2020 +22% 2021: -$18.8M -$18.8M 2021 +24% 2022: -$19.9M -$19.9M 2022 +6% 2023: -$31.9M -$31.9M 2023 +60% 2024: -$19.8M -$19.8M 2024 −38% 2025: -$11.7M -$11.7M 2025 −41% Net income4 5 6 7 8 3 -$14.0M in 2025+48% since 2019 -$30.0M -$20.0M -$10.0M 0 2019: -$9.4M -$9.4M 2019 2020: -$14.4M -$14.4M 2020 +53% 2021: -$19.1M -$19.1M 2021 +33% 2022: -$19.4M -$19.4M 2022 +2% 2023: -$29.0M -$29.0M 2023 +49% 2024: -$17.3M -$17.3M 2024 −40% 2025: -$14.0M -$14.0M 2025 −19% Revenue9 10 $26.0K in Q2 FY2026+18% since Q1 FY2026 0 $10.0K $20.0K $30.0K Q1 FY2026: $22.0K $22.0K Q1 FY2026 Q2 FY2026: $26.0K $26.0K Q2 FY2026 +18% Operating income9 10 -$3.5M in Q2 FY2026+58% since Q1 FY2026 -$4.0M -$3.0M -$2.0M -$1.0M 0 Q1 FY2026: -$2.2M -$2.2M Q1 FY2026 Q2 FY2026: -$3.5M -$3.5M Q2 FY2026 +58% Net income9 10 -$3.8M in Q2 FY2026+25% since Q1 FY2026 -$4.0M -$3.0M -$2.0M -$1.0M 0 Q1 FY2026: -$3.0M -$3.0M Q1 FY2026 Q2 FY2026: -$3.0M -$3.0M Q2 FY2026 +0% Q2 FY2026: -$3.8M -$3.8M Q2 FY2026 +25% Fiscal year 2019 2020 2021 2022 2023 2024 2025 Revenue $140.0K4 $163.0K5 $135.0K6 $141.0K7 $202.0K8 $170.0K3 $88.0K3 Cost of revenue Research and development $4.7M4 $5.7M5 $7.7M6 $7.0M7 $10.9M8 $6.2M3 $3.9M3 Operating income -$12.4M4 -$15.2M5 -$18.8M6 -$19.9M7 -$31.9M8 -$19.8M3 -$11.7M3 Interest $427.0K4 $672.0K5 $67.0K6 $585.0K3 $812.0K3 Net income -$9.4M4 -$14.4M5 -$19.1M6 -$19.4M7 -$29.0M8 -$17.3M3 -$14.0M3 Earnings per share -$0.406 -$0.407 -$0.608 -$30.923 -$8.623 Earnings per share (diluted) -$0.407 -$0.608 -$30.923 -$8.623
Total assets4 5 6 7 8 3 $5.8M in 2025−72% since 2019 0 $20.0M $40.0M $60.0M $80.0M 2019: $20.8M $20.8M 2019 2020: $64.6M $64.6M 2020 +211% 2021: $57.7M $57.7M 2021 −11% 2022: $40.5M $40.5M 2022 −30% 2023: $19.4M $19.4M 2023 −52% 2024: $8.6M $8.6M 2024 −56% 2025: $5.8M $5.8M 2025 −33% Total liabilities7 8 3 $15.6M in 2025+671% since 2022 0 $5.0M $10.0M $15.0M $20.0M 2022: $2.0M $2.0M 2022 2023: $9.1M $9.1M 2023 +353% 2024: $9.9M $9.9M 2024 +9% 2025: $15.6M $15.6M 2025 +57% Shareholders’ equity5 6 7 8 3 -$9.8M in 2025-$20.0M 0 $20.0M $40.0M $60.0M $80.0M 2019: $13.4M $13.4M 2019 2020: $61.3M $61.3M 2020 +356% 2021: $56.9M $56.9M 2021 −7% 2022: $38.5M $38.5M 2022 −32% 2023: $10.2M $10.2M 2023 −73% 2024: -$1.3M -$1.3M 2024 2025: -$9.8M -$9.8M 2025 +640% Cash4 5 6 7 8 3 $3.0M in 2025+103% since 2019 0 $10.0M $20.0M $30.0M $40.0M 2019: $1.5M $1.5M 2019 2020: $38.5M $38.5M 2020 +2519% 2021: $32.1M $32.1M 2021 −17% 2022: $27.1M $27.1M 2022 −16% 2023: $5.4M $5.4M 2023 −80% 2024: $1.7M $1.7M 2024 −69% 2025: $3.0M $3.0M 2025 +75% Long-term debt4 5 3 $927.0K in 2025−56% since 2019 0 $1.0M $2.0M $3.0M 2019: $2.1M $2.1M 2019 2020: $1.9M $1.9M 2020 −11% 2024: $2.8M $2.8M 2024 +50% 2025: $927.0K $927.0K 2025 −67% Total assets9 10 $12.7M in Q2 FY2026+120% since Q1 FY2025 0 $5.0M $10.0M $15.0M Q1 FY2025: $5.8M $5.8M Q1 FY2025 Q2 FY2025: $5.8M $5.8M Q2 FY2025 +0% Q1 FY2026: $8.6M $8.6M Q1 FY2026 +48% Q2 FY2026: $12.7M $12.7M Q2 FY2026 +48% Total liabilities9 10 $5.0M in Q2 FY2026−68% since Q1 FY2025 0 $5.0M $10.0M $15.0M $20.0M Q1 FY2025: $15.6M $15.6M Q1 FY2025 Q2 FY2025: $15.6M $15.6M Q2 FY2025 +0% Q1 FY2026: $6.5M $6.5M Q1 FY2026 −58% Q2 FY2026: $5.0M $5.0M Q2 FY2026 −23% Shareholders’ equity9 10 $7.7M in Q2 FY2026-$10.0M -$5.0M 0 $5.0M $10.0M Q1 FY2025: -$9.8M -$9.8M Q1 FY2025 Q2 FY2025: -$9.8M -$9.8M Q2 FY2025 +0% Q1 FY2026: $2.1M $2.1M Q1 FY2026 Q2 FY2026: $2.1M $2.1M Q2 FY2026 +0% Q2 FY2026: $7.7M $7.7M Q2 FY2026 +264% Cash9 10 $9.9M in Q2 FY2026+232% since Q1 FY2025 0 $2.5M $5.0M $7.5M $10.0M Q1 FY2025: $3.0M $3.0M Q1 FY2025 Q2 FY2025: $3.0M $3.0M Q2 FY2025 +0% Q1 FY2026: $5.8M $5.8M Q1 FY2026 +95% Q2 FY2026: $9.9M $9.9M Q2 FY2026 +70% Long-term debt9 10 $3.6M in Q2 FY2026+291% since Q1 FY2025 0 $1.0M $2.0M $3.0M $4.0M Q1 FY2025: $927.0K $927.0K Q1 FY2025 Q2 FY2025: $927.0K $927.0K Q2 FY2025 +0% Q1 FY2026: $210.0K $210.0K Q1 FY2026 −77% Q2 FY2026: $3.6M $3.6M Q2 FY2026 +1624% Fiscal year 2019 2020 2021 2022 2023 2024 2025 Cash $1.5M4 $38.5M5 $32.1M6 $27.1M7 $5.4M8 $1.7M3 $3.0M3 Current assets $10.4M4 $40.3M5 $50.2M6 $36.3M7 $14.6M8 $4.2M3 $3.3M3 Total assets $20.8M4 $64.6M5 $57.7M6 $40.5M7 $19.4M8 $8.6M3 $5.8M3 Current liabilities $1.1M4 $1.1M5 $673.0K6 $1.4M7 $8.7M8 $9.5M3 $6.2M3 Long-term debt $2.1M4 $1.9M5 $2.8M3 $927.0K3 Total liabilities $2.0M7 $9.1M8 $9.9M3 $15.6M3 Shareholders’ equity $13.4M5 $61.3M6 $56.9M7 $38.5M8 $10.2M3 -$1.3M3 -$9.8M3 Shares outstanding 10.4M shares4 42.2M shares5 48.0M shares6 48.1M shares7 49.1M shares8 655.3K shares3 3.1M shares3
Cash from operations4 5 6 7 8 3 -$11.0M in 2025+21% since 2019 -$30.0M -$20.0M -$10.0M 0 2019: -$9.1M -$9.1M 2019 2020: -$10.4M -$10.4M 2020 +14% 2021: -$14.0M -$14.0M 2021 +35% 2022: -$16.1M -$16.1M 2022 +15% 2023: -$21.3M -$21.3M 2023 +32% 2024: -$14.9M -$14.9M 2024 −30% 2025: -$11.0M -$11.0M 2025 −26% Capital spending4 5 6 7 3 $18.0K in 2024−74% since 2019 0 $25.0K $50.0K $75.0K $100.0K 2019: $68.0K $68.0K 2019 2020: $22.0K $22.0K 2020 −68% 2021: $41.0K $41.0K 2021 +86% 2022: $86.0K $86.0K 2022 +110% 2024: $18.0K $18.0K 2024 −79% Free cash flow4 5 6 7 3 -$14.9M in 2024+63% since 2019 -$20.0M -$15.0M -$10.0M -$5.0M 0 2019: -$9.1M -$9.1M 2019 2020: -$10.4M -$10.4M 2020 +14% 2021: -$14.0M -$14.0M 2021 +35% 2022: -$16.2M -$16.2M 2022 +16% 2024: -$14.9M -$14.9M 2024 −8% Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Fiscal year 2019 2020 2021 2022 2023 2024 2025 Cash from operations -$9.1M4 -$10.4M5 -$14.0M6 -$16.1M7 -$21.3M8 -$14.9M3 -$11.0M3 Capital spending $68.0K4 $22.0K5 $41.0K6 $86.0K7 $18.0K3 Free cash flow -$9.1M -$10.4M -$14.0M -$16.2M -$14.9M
Compare AIM ImmunoTech Inc. with another company
Former names
HEMISPHERX BIOPHARMA INC Sep 30, 1996 to Aug 26, 20192
Recent filings
Sep 30, 2026 DEF 14A Sep 30, 2026 ARS Sep 18, 2026 4 Sep 17, 2026 4 Sep 16, 2026 4 Sep 15, 2026 4 Sep 14, 2026 8-K Sep 10, 2026 8-K Sep 4, 2026 8-K Aug 11, 2026 8-K Aug 10, 2026 8-K Aug 7, 2026 10-Q Aug 6, 2026 8-K Aug 5, 2026 8-K Jul 16, 2026 8-K Every filing from the last three years, summarized . The full record is on SEC EDGAR.1
